𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Autobahn Therapeutics, Inc. announced a $100M series C this week as it prepares to move its thyromimetic into phase 2 for MDD and bipolar disorder depression. CEO Kevin Finney describes the rationale for using a TRβ agonist and how this program leverages Autobahn's brain-targeting chemistry platform. Plus, how the funding will also allow the company to advance a S1P receptor modulator. Full video: https://lnkd.in/gdCkzhS7 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
About us
News, stories, and educational videos about the biotechnology sector. Bringing biotech to life. 📺
- Website
-
https://www.biotechtv.com
External link for BiotechTV
- Industry
- Internet News
- Company size
- 2-10 employees
- Headquarters
- Seaport, Boston
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Biotech and News
Locations
-
Primary
Seaport, Boston, US
Employees at BiotechTV
Updates
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Bessemer Venture Partners' Morgan Cheatham shares his take on AI in life sciences. He talks about the two different categories of companies based on their use of AI, and discusses what he looks for when evaluating them. Full video: https://lnkd.in/gNDG-yVV BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Kernal Biologics co-founder Yusuf Erkul describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body. He explains the four components that go into getting mRNA to the right location in the body and to be translated in the right cells, and how technology is allowing the company to do this work today. Full video: https://lnkd.in/gK7MVivp BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Generate:Biomedicines' CEO Michael Nally gives an update on the company's clinical and emerging programs. He describes clinical programs targeting COVID and TSLP, as well as emerging programs in the ADC space, TL1A, IL13, and more. Full video: https://lnkd.in/gPFP2yEK BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Co-Founder Transon Nguyen describes how AI is enabling Eigen Therapeutics to become a discovery engine for priming therapies. He explains how the goal of Eigen is to help up-regulate antigens of interest and how technologies today allow a smaller startup to derive and test large datasets. Full video: https://lnkd.in/g55Jh67m BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: The Co-Hosts of the AI x Bio Summit at NYSE talk about the conference and their take on AI. NYSE's Eric J. Dimise, PhD and Decoding Bio's Amee Kapadia describe the ways that AI is already impacting healthcare today and where it might be headed in the future. Full video: https://lnkd.in/gtm3jMRi BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Philadelphia area based XyloCor Therapeutics, Inc. is developing a gene therapy with the goal of helping to revascularize the heart for refractory angina patients. CEO Al Gianchetti explains that the company recently released final results from a phase 1/2 clinical trial and how XyloCor is set to begin a new study utilizing a catheter system that does not require open heart surgery for delivery. Full video: https://lnkd.in/g_ADHVMV BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐔𝐊 𝐁𝐢𝐨𝐭𝐞𝐜𝐡: This week our UK based correspondent Amy Brown visited Stevenage Bioscience Catalyst, a key life sciences research campus in the UK. Entrepreneurship and Business Development Director Marco Delise, PhD describes the facilities available at SBC and the types of companies that are housed here. Full video: https://lnkd.in/gi3thjWZ BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: GRO Biosciences announced a $60 million series B today to help advance its pipeline that is rooted in adding non-standard amino acid (NSAA) chemistries to therapies. Co-founder and CEO Dan Mandell discusses the company’s approach, and describes how this will allow GRO to advance its lead program for gout into the clinic to proof of concept, as well as expand the company’s pipeline. Full video: https://lnkd.in/gP_i-Phd BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Click Therapeutics, Inc. founder David Benshoof Klein on the digital therapeutics space and the regulatory opportunity for combining medicines with apps. He describes how the digital therapeutics space works and highlights Click's programs and partnerships with large pharmaceutical companies. Full video: https://lnkd.in/gWgGqYze BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent